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ABSTRACT: Reproducible, comprehensive phosphopeptide enrichment is essential
for studying phosphorylation-regulated processes. Here, we describe the application of
hyper-porous magnetic TiO2 and Ti-IMAC microspheres for uniform automated
phosphopeptide enrichment. Combining magnetic microspheres with a magnetic
particle-handling robot enables rapid (45 min), reproducible (r2 ≥ 0.80) and high-
ﬁdelity (>90% purity) phosphopeptide puriﬁcation in a 96-well format. Automated
phosphopeptide enrichment demonstrates reproducible synthetic phosphopeptide
recovery across 2 orders of magnitude, “well-to-well” quantitative reproducibility
indistinguishable to internal SILAC standards, and robust “plate-to-plate” reproduci-
bility across 5 days of independent enrichments. As a result, automated phosphopeptide
enrichment enables statistical analysis of label-free phosphoproteomic samples in a high-
throughput manner. This technique uses commercially available, oﬀ-the-shelf
components and can be easily adopted by any laboratory interested in
phosphoproteomic analysis. We provide a free downloadable automated phosphopeptide enrichment program to facilitate
uniform interlaboratory collaboration and exchange of phosphoproteomic data sets.
Post-translational protein phosphorylation is an importantmedium for cellular signal transduction.1 Protein kinases
and phosphatases are often deregulated in disease, and
pharmacological modulation of phosphorylation-dependent
signal transduction is an active area of research.2 Consequently,
quantitative analysis of pathological phosphoproteomes is of
substantial interest to the biological research community.
Liquid chromatography coupled tandem mass spectrometry
(LC-MS/MS) is a powerful technology used to characterize
and quantify phosphorylated proteins. However, given the low
stoichiometric abundance of phosphorylated residues within
the proteome, phosphopeptide enrichment is required for
comprehensive phosphoproteomic analysis. Due to the
complexity and dynamic range of the phosphoproteome,
sample prefractionation is commonly used to obtain
comprehensive coverage.3 Popular prefractionation techniques
include strong cation exchange (SCX),4 hydrophilic interaction
liquid chromatography (HILIC),5 and electrostatic repulsion
hydrophilic interaction chromatography (ERLIC).6 Subsequent
aﬃnity-based phosphopeptide enrichment commonly employs
metal dioxides (such as titanium and zirconium) or
immobilized metal ion aﬃnity chromatography (IMAC).7−11
Despite the established performance of these matrices, a limited
number of workﬂows have been developed for automa-
tion.12−14 Consequently, existing aﬃnity enrichment method-
ologies still operate in either manual batch-mode or as manual
prepacked spin-columns.
Extensive upstream chromatographic separation massively
expands the number of samples for phosphopeptide enrich-
ment processing. Successful approaches to avoid prefractiona-
tion have been reported for samples with limited input
variables.15,16 However, these methods do not facilitate the
uniform parallel phosphopeptide enrichments required for the
increased numbers of biological variables/replicates now
common in phosphoproteomics. Such multivariate expansions
are further exacerbated by the contemporary trend toward
multisite proteomic projects.17−19 These endeavors require
interlaboratory integration of large sample sets and demand
invariable sample processing across disparate users. Collec-
tively, these factors increase both the number of simultaneous
phosphopeptide enrichments required for phosphoproteomic
analysis and the demand for uniﬁed sample-to-sample enrich-
ment.
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Terms of Use
Large-scale manual phosphopeptide enrichment suﬀers from
limited throughput and may inadvertently introduce sample-to-
sample enrichment bias. To address these limitations, a high-
performance, easily operated, and technically uniform method
for phosphopeptide enrichment is desirable.
Here, we report the application of magnetic hyper-porous
polymer matrix microspheres for high-throughput, reproducible
phosphopeptide enrichment. We characterize the performance
of both TiO2 and Ti-IMAC aﬃnity matrices and describe how
hyper-porous magnetic microspheres can be coupled to a
magnetic particle-processing robot to facilitate automated
phosphopeptide enrichment. We provide a free downloadable
program so that this method can be reproduced across
laboratories. The workﬂow employs noncustom, oﬀ-the-shelf
equipment and is accessible to any laboratory interested in
phosphopeptide analysis.
■ EXPERIMENTAL SECTION
Automated Phosphopeptide Enrichment. All experi-
ments were performed with a KingFisher Flex (Thermo
Scientiﬁc) magnetic particle-processing robot. The automated
phosphopeptide enrichment program was developed using
BindIt Software 3.0 (Thermo Scientiﬁc). The program ﬁle has
been uploaded alongside the MS/MS data (see below) with the
identiﬁer Automated_Phosphopeptide_Enrichment.msz. This
program can be freely downloaded and run on any KingFisher
Flex system. TiO2 (MR-TID010) and Ti-IMAC (MR-TIM010)
hyper-porous magnetic microspheres were purchased from
ReSyn Biosciences. The KingFisher Flex was conﬁgured for
automated phosphopeptide enrichment, as illustrated in Figure
1a. In brief, deep-well 96-well plates (VWR 733-3004) were
assigned to each of the eight carousel positions. Individual
positions were loaded with (1) 96-well tip heads (Thermo
Scientiﬁc); (2) hyper-porous magnetic microspheres (in 100%
MeCN); (3) wash buﬀer 1 (80% MeCN, 5% TFA, + 1 M
glycolic acid); (4) 100 μg Lys-C/trypsin digested lysate (in
80% MeCN, 5% TFA, + 1 M glycolic acid); (5) wash buﬀer 1;
(6) wash buﬀer 2 (80% MeCN, 1% TFA); (7) wash buﬀer 3
(10% MeCN, 0.2% TFA); and (8) elution buﬀer (1−5%
NH4OH). 500 μL of the relevant buﬀer was added to each
well, except for the sample binding and elution steps, where
only 200 μL of sample and elution buﬀer were used. Unless
stated otherwise, all experiments were performed with the
buﬀers described above, 1 mg of magnetic microspheres, and
three automated phosphopeptide enrichment cycles. (Techni-
cal note: The amount of microspheres can greatly aﬀect
enrichment performance.20 For maximum sample-to-sample
ﬁdelity, vortex the microsphere slurry before aliquoting.)
Following each enrichment cycle, phosphopeptides fractions
were immediately acidiﬁed to 0.5% TFA/10% FA, desalted
using OLIGO R3 resin21 (Life Technologies 1-1339-03), and
lyophilized. Samples were resuspended in 0.1% formic acid
prior to analysis by LC-MS/MS.
Additional materials and methods can be found in the
Supporting Information.
■ RESULTS AND DISCUSSION
Performance of Magnetic Hyper-Porous TiO2 and Ti-
IMAC Microspheres. Advances in emulsion-derived particle
development have permitted the production of hyper-porous
cross-linked polymeric lattices.22 This technology has recently
been used to generate metal-dioxide-bound magnetic micro-
spheres for phosphopeptide enrichment. To evaluate the
phosphopeptide enrichment performance of these matrices,
TiO2, ZrO2, and Ti-IMAC hyper-porous magnetic micro-
spheres (MagReSyn) were compared to established solid-bead
phospho-aﬃnity reagents (GL Science Titansphere TiO2 and
GE Healthcare MagSeph TiO2). For each comparison, 1 mg of
microspheres was combined with 500 μg of human tryptic
digest, and the manufacturer’s protocol was followed.
To track phosphopeptide retention, we ﬁrst incubated each
product with 500 μg of 32P-labeled cell lysates in manual batch
mode, washed and eluted. “Unbound” (remaining in the tube),
“bound” (remaining on the microspheres), and “eluted” 32P-
containing material was quantiﬁed using a scintillation counter
(Supplementary Figure 1a, Supporting Information). Elution
eﬃciency was higher from magnetic Ti-IMAC (MagReSyn),
followed by Titansphere TiO2 (GL) and magnetic TiO2
(MagReSyn). Both the ZrO2 (MagReSyn) and magnetic-
sepharose TiO2 (GE) displayed poorer phosphopeptide
elution. Less material was retained on the hyper-porous
magnetic TiO2, ZrO2, and Ti-IMAC matrices following elution
Figure 1. Robotic magnetic automated phosphopeptide enrichment.
(a) KingFisher Flex conﬁgured for automated phosphopeptide
enrichment. (b) Automated phosphopeptide enrichment steps
(program has been deposited in PRIDE: PXD000892). (c) 100 μg
and 500 μg of a common tryptic digest was phospho-enriched using
TiO2 and Ti-IMAC hyper-porous microspheres via manual and
automated methods and analyzed by LC-MS/MS. DDA runs, red dots,
n = 24.
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than on the nonmagnetic TiO2 (GL) and magnetic-sepharose
TiO2 (GE).
To investigate how this behavior translated to unique
phosphopeptide identiﬁcation, we repeated these experiments
and analyzed eluted samples by LC-MS/MS. The highest
numbers of unique phosphopeptides were identiﬁed using Ti-
IMAC (MagReSyn), followed by TiO2 (MagReSyn), ZrO2
(MagReSyn), Titansphere TiO2 (GL science) and MagSeph
TiO2 (GE) (Supplementary Figure 1b, Supporting Informa-
tion). Unfortunately, as the total surface area and chemical
composition of these reagents is proprietary, the mechanism
underlying this improved performance is currently unclear.
When compared to all other microspheres, Ti-IMAC
(MagReSyn) and TiO2 (MagReSyn) demonstrate a ∼15%
preference for acidic residues C-terminal of the phosphor-
ylation (Supplementary Figure 1c, Supporting Information).
Conversely, TiO2 (GL) and TiO2 (GE) display a ∼15% bias for
proline at position +1 and ∼2−5% preference for basic residues
C-terminal of the phosphorylation. This data suggests the
structural matrix supporting the primary enrichment chemistry
inﬂuences phosphopeptide aﬃnity. In agreement with a recent
comprehensive enrichment bias study,23 Ti-IMAC (MagRe-
Syn) and TiO2 (MagReSyn) display minimal phosphopeptide
biases.
Given their capacity to enrich substantial numbers of high-
ﬁdelity phosphopeptides at high purity (>80%), we concluded
magnetic hyper-porous Ti-IMAC and TiO2 microspheres
(MagResyn) are suitable for high-performance phosphopeptide
enrichment.
Automated Phosphopeptide Enrichment. Given the
high performance of magnetic TiO2 and Ti-IMAC hyper-
porous microspheres in manual batch mode, we hypothesized
these reagents might be applicable to automated phosphopep-
tide enrichment using a magnetic particle processing robot. To
investigate this, we reformatted the manual phosphopeptide
enrichment protocol for automated use on the KingFisher Flex
(Thermo Scientiﬁc). The KingFisher Flex contains eight
positions that each hold a single deep 96-well plate. Each
plate can be rotated into position under a 96-pin magnetic head
via a central carousel. Once aligned, the 96-pin magnetic head
drops down inside the 96-well plate to release, bind, or agitate
the magnetic microspheres in solution. By repeating these steps
in a user-deﬁned sequence, the KingFisher Flex can transfer 96
magnetic microsphere samples between eight diﬀerent
solutions in a fast and uniform manner. We conﬁgured this
platform to perform automated phosphopeptide enrichment by
adding established phosphopeptide enrichment buﬀers to each
plate and writing a program to transfer TiO2/Ti-IMAC hyper-
porous microspheres between the diﬀerent plates.
Magnetic TiO2/Ti-IMAC hyper-porous microspheres were
added to one plate (position 2), Lys-C/trypsin digested
samples were added in a separate plate (position 4),
phosphopeptide enrichment wash buﬀers were dispensed into
several plates (positions 3, 5, 6, and 7), and ammonia elution
buﬀer to the ﬁnal plate (position 8). We then compiled a
program to collect the TiO2/Ti-IMAC microspheres from
position 2, wash the microspheres in position 3, incubate them
with the tryptic digest in position 4, wash the microspheres
(now containing bound phosphopeptides) in positions 5−7,
elute the phosphopeptides in position 8 and return the
microspheres to position 2 (Figure 1a,b). This program permits
the concurrent phosphopeptide enrichment of 96 samples in 45
min. To facilitate uniform interlaboratory operation, we have
deposited the automated phosphopeptide enrichment program
alongside all LC-MS/MS data (PRIDE: PXD000892). This
program can be freely downloaded and replicated on any
KingFisher Flex system.
Automated Phosphopeptide Enrichment Optimiza-
tion. As buﬀer composition can substantially aﬀect enrichment
performance,24 we ﬁrst trialled the automated phosphopeptide
enrichment program under diﬀerent binding and elution
conditions. Previous studies suggest that glycolic acid (GA)
added to the binding buﬀer can improve phosphopeptide
enrichment eﬃciency from TiO2.
24 However, GA is not
currently used for Ti-IMAC enrichments.25 Moreover, while
low concentrations of ammonia solution (∼1% v/v) have been
reported for elution of phosphopeptides from TiO2,
21 much
higher concentrations have been used for Ti-IMAC (∼5−10%
v/v).25,26 To deduce the optimal buﬀer conditions for
automated phosphopeptide enrichment, we screened multiple
ammonia solutions (1, 2.5, and 5 v/v) with or without 1 M GA
across both TiO2 and Ti-IMAC matrices (Supplementary
Figure 2, Supporting Information). To ensure experiments
were not limited by predicted microsphere capacity (500 μg of
peptides/1 mg of microspheres), we used 20% of the
recommend tryptic digest input (100 μg of peptides/1 mg of
microspheres).
First, these results conﬁrm magnetic TiO2/Ti-IMAC hyper-
porous microspheres are applicable to robotic automated
phosphopeptide enrichment. This analysis also conﬁrmed that
GA improves phosphopeptide purity when using TiO2 and
revealed that GA has little inﬂuence on phosphopeptide purity
when using Ti-IMAC. Moreover, increasing the ammonia
concentration in the elution buﬀer reduces total phosphopep-
tide numbers with both TiO2 and Ti-IMAC. Consequently, we
opted to use 1 M GA loading buﬀer and 1% ammonia elution
buﬀer (as also used in a manual method24) for all TiO2 and Ti-
IMAC automated phosphopeptide enrichments.
Successive Automated Phosphopeptide Enrichment
Cycles. Following the completion of a single 45 min
automated phosphopeptide enrichment cycle, the KingFisher
Flex robot can be immediately restarted to perform an
additional enrichment cycle. It has previously been shown
that successive rounds of manual enrichment can increase
phosphopeptide isolation.27 We subsequently hypothesized that
successive enrichment cycles inﬂuence phosphopeptide recov-
ery using the automated platform. To investigate this, we
performed successive automated phosphopeptide enrichments
and independently analyzed the elution from each cycle by LC-
MS/MS. To investigate the inﬂuence of increasing the amount
of magnetic TiO2 and Ti-IMAC during repeat binding, we
performed this analysis with 1, 2, and 3 mg of magnetic
microspheres (Supplementary Figure 3, Supporting Informa-
tion).
In all experiments, the highest numbers of unique
phosphopeptides were identiﬁed in the ﬁrst cycle. However,
successive cycles continued to enrich both cumulatively unique
and nonunique phosphopeptides. Increasing the amount of
magnetic microspheres also increased the total number of
uniquely identiﬁed phosphopeptides. While additional DDA
LC-MS/MS runs could explain the increase in cumulative
peptides, repeated cycles also enrich smaller, lower charge-state
phosphopeptides (Supplementary Figure 4, Supporting In-
formation). Although successive enrichment cycles continue to
enrich phosphopeptides, repeat bindings beyond two to three
cycles do not increase the cumulative number of unique
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phosphopeptides. Phosphopeptide purity decreases with each
enrichment cycle and increasing microsphere input exacerbates
this deterioration. The reduction in phosphopeptide purity is
particularly pronounced when using Ti-IMAC.
As the number of enrichable phosphopeptides will vary
between diﬀerent biological samples, we advise future users of
the automated phosphopeptide enrichment protocol to validate
how many cycles are required for maximum phosphopeptide
enrichment of their speciﬁc samples. We concluded that one
cycle of puriﬁcation was suitable for most applications, and two
to three cycles can be used when maximum phosphopeptide
recovery is paramount.
Distinct phosphopeptide enrichment chemistries have been
reported to enrich complementary segments of the phospho-
proteome.21,28,29 We subsequently hypothesized that the
automated phosphopeptide enrichment platform could operate
with mixed TiO2 and Ti-IMAC microspheres. To investigate
this, we performed automated phosphopeptide enrichment
with titrated ratios of each microsphere matrix. Interestingly, we
observed an increase in the number of unique phosphopeptides
identiﬁed from a mix of TiO2 and Ti-IMAC compared to their
individual use (Supplemental Figure 5, Supporting Informa-
tion). As the automated phosphopeptide enrichment platform
can operate with any high-performance magnetic microspheres,
this protocol can be easily adapted to employ diﬀerent
enrichment materials. It will be interesting to investigate
alternative chemistries (as they become available) in future
experiments.
Manual versus Automated Phosphopeptide Enrich-
ment. To directly investigate how manual enrichment
compared to the automated platform, we simultaneously
phospho-enriched 100 and 500 μg of a consistent tryptic
digest using both methods and sequentially analyzed the
samples by LC-MS/MS (Figure 1c). This concurrent analysis
demonstrated comparable phosphopeptide enrichment be-
tween manual and automated methods. Consequently, we
concluded that the automated phospho enrichment platform
performs analogous phosphopeptide identiﬁcation to existing
manual methodology.
Automated Phosphopeptide Enrichment Recovery.
While multiple approaches for phosphopeptide enrichment are
currently in use, most evaluate phosphopeptide recovery using
data-dependent analysis (DDA). As such, it can be diﬃcult to
discern whether methodological improvements are due to
diﬀerences in the phosphopeptide enrichment protocol or in
the LC-MS/MS setup. To determine phosphopeptide recovery
from the automated phosphopeptide enrichment platform, we
established a targeted selected reaction monitoring (SRM)
assay to robustly quantify a selection of human synthetic
phosphopeptides (Supplementary Table 1 and Supplementary
Figure 6, Supporting Information). To investigate the inﬂuence
of phosphopeptide starting concentration, 5, 10, 100, and 500
fmol synthetic human phosphopeptides were spiked-in to a
SILAC “heavy” (K +8 Da; R +10 Da) complex mouse cell-
lysate tryptic digest matrix either before or after automated
phosphopeptide enrichment (Figure 2a). Percentage recovery
was calculated by comparing the intensity of each phosphopep-
tide spiked-in before automated enrichment to its standard
curve derived from phosphopeptides spiked-in after enrichment
(Supplementary Figure 7a, Supporting Information). Synthetic
phosphopeptides were enriched with either TiO2 (Figure 2b),
Ti-IMAC (Figure 2c), or a combination of TiO2 and Ti-IMAC
(Figure 2d). Automated phosphopeptide enrichment recovered
between 20 and 80% of the phosphopeptides tested with
intrapeptide mean coeﬃcient of variation (CV) of 11−46%
(Supplementary Table 2, Supporting Information). All three
phosphopeptide enrichment workﬂows demonstrated a repro-
ducible, linear dynamic range across 2 orders of magnitude
(Supplementary Figure 7b and Supplementary Table 3,
Supporting Information). While this synthetic phosphopeptide
portfolio is not extensive enough to extrapolate which
phosphopeptide sequences are more suitable for Ti-IMAC or
TiO2 based enrichment, this data suggests some phosphopep-
tides are more amendable to enrichment than others. Despite
this sequence-speciﬁc enrichment behavior, phosphopeptide
recovery was independent of starting concentration for all
phosphopeptides. Given the robust reproducibility and linearity
of this assay, these synthetic phosphopeptides (Figure 2 and
Supplemental Table 1, Supporting Information) also provide an
accessible common standard for interlaboratory implementa-
tion of the automated phosphopeptide enrichment platform.
Figure 2. Automated phosphopeptide enrichment recovery. (a) Titrated synthetic phosphopeptides (n = 10) were spiked into 100 μg of heavy (K
+8 Da; R +10 Da) tryptic digests either (left, standard curve) after or (right, recovery samples) before automated phosphopeptide enrichment
(technical n = 3/phosphopeptide). Synthetic phosphopeptide abundance was then measured by SRM. Synthetic phosphopeptide recovery by (b)
TiO2, (c) Ti-IMAC, and (d) combined TiO2 and Ti-IMAC automated phosphopeptide enrichment. Each dot represents the mean phosphopeptide
recovery (technical n = 3) when spiked-in at 5, 10, 100, or 500 fmol. (Phosphopeptide linearity in Supplementary Table 3, Supporting Information.)
LC-MS/MS SRM runs n = 51.
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Automated Phosphopeptide Enrichment Intra-Plate
Reproducibility. As the automated phosphopeptide enrich-
ment platform subjects each well to identical conditions (e.g.,
uniform incubation times, agitation frequencies, cycles, etc.), we
hypothesized this technique enriches well-to-well phosphopep-
tides in a highly reproducible manner. To investigate intraplate
ﬁdelity, we used the automated phosphopeptide enrichment
platform to compare a “gold standard” standard SILAC
experiment (samples mixed prior to enrichment)30 with a
“split” SILAC experiment (samples combined postenrichment).
To this end, we compared the relative “light”/“heavy” ratios of
two distinct SILAC populations mixed either before (premixed)
or after (postmixed) enrichment (Figure 3a) (n = 3/group). To
simulate a typical biological experiment and evaluate the
dynamic range of the workﬂow, light labeled cells were treated
with 100 ng/mL EGF for 5 min, and heavy labeled cells were
left untreated. In agreement with earlier experiments, this
analysis conﬁrmed intraplate technical replicates enrich
approximately equal numbers of unique phosphopeptides at
high purity (>90% phosphorylated peptides) (Figure 3b).
Crucially, correlating the light/heavy ratios of premixed and
postmixed phosphopeptide samples showed no discernible
diﬀerence in phosphopeptide enrichment ﬁdelity between
replicates (r2 = 0.80) (Figure 3c−e). As a result, we propose
automated magnetic particle handling as a highly reproducible
platform for uniform intraplate phosphopeptide enrichment.
Automated Phosphopeptide Enrichment Interplate
Reproducibility. In addition to well-to-well intraplate
consistency, the automated phosphopeptide enrichment
program also performs identical enrichments across each
individual cycle. As such, we hypothesized the automated
phosphopeptide enrichment method produces high plate-to-
plate enrichment reproducibility. To investigate interplate
ﬁdelity, we divided a single unlabeled tryptic digest into 5
aliquots and performed automated phosphopeptide enrichment
on each aliquot across 5 consecutive days. Enrichments were
conducted using TiO2 (Figure 4a), Ti-IMAC (Figure 4b), and a
mixture of TiO2 and Ti-IMAC (Figure 4c; n = 3/condition/
day). The respective MS1 precursor areas for each
phosphopeptide were subsequently correlated across all 5
days. This experiment conﬁrmed interplate replicates enrich
approximately equal numbers of unique phosphopeptides at
high ﬁdelity (>90% phosphorylated peptides). Moreover, by
correlating the MS1 precursor areas for each phosphopeptide
across all 5 days, this analysis conﬁrmed the automated
phosphopeptide enrichment platform performs highly reprodu-
cible interplate phosphopeptide enrichment (TiO2 x ̅ r2 = 0.78,
Ti-IMAC x ̅ r2 = 0.81, TiO2 + Ti-IMAC x ̅ r2 = 0.85). This high
reproducibility suggests automated phosphopeptide enrichment
could be applicable to accurate intraplate and interplate label-
free phosphoproteomic analysis. As multiple phosphopeptide
enrichments are likely to be performed over diﬀerent days
during a real biological project, this data also suggests
phosphopeptides will be uniformly enriched across multiple
experiments.
Moreover, the high interplate reproducibility suggests
consistent interlaboratory exchange of data across multiple
operators is possible. As a result, we propose automated
magnetic particle handling as a highly robust platform for
reproducible interplate phosphopeptide enrichment.
Automated Phosphopeptide Enrichment For Label-
Free Quantitative Phosphoproteomics. Given the ex-
cellent reproducibility, we hypothesized that automated
phosphopeptide enrichment can be used for multivariate
label-free quantitative phosphoproteomics. To investigate this
in a relevant biological system, we studied phosphorylation-
dependent signaling of oncogenic KRAS (KRAS-G12D) in
pancreatic ductal adenocarcinoma (PDA) cells. KRAS-G12D is
the primary driving oncogenic mutation in PDA31,32 and
underpins aberrant cellular signaling.
Three distinct isolations of KRAS-G12D inducible cells
(iKRAS)31 were switched between KRAS-WT and KRAS-
Figure 3. Automated phosphopeptide enrichment intra-plate reproducibility. (a) Light KPC cells were treated with 100 ng/mL EGF for 5 min and
SILAC heavy (K +8 Da; R +10 Da) KPC cells were left untreated. Each SILAC population was digested separately and mixed either before
(premixed, green) or after (postmixed, blue) automated magnetic TiO2 phosphopeptide enrichment. Phosphopeptides were then analyzed by DDA
LC-MS/MS. (b) Pre- and postmixed samples were randomly divided into two groups (A and B; n = 3/group). (c−e) The light/heavy SILAC ratios
of each population were assessed by Pearson correlation (two-tailed P < 0.0001). LC-MS/MS DDA runs n = 12.
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G12D (via doxycycline; Supplementary Figure 8, Supporting
Information) for 24 h, harvested and processed for automated
phosphopeptide enrichment. Samples were prepared in bio-
logical and technical triplicate from each cell isolation (total
unique phosphopeptide samples n = 54) (Figure 5a). LC-MS/
MS MS1 phosphopeptide precursor area quantiﬁcation
revealed broad diﬀerential phospho-regulation across all three
cell isolations following oncogenic KRAS induction (Supple-
mentary Figure 9a, Supporting Information). Total phospho-
proteomic phenotypes resolved oncogenic genotypes in
principle component analysis (PCA) space (Figure 5b and
Supplementary Figure 9b, Supporting Information). Moreover,
given the high technical reproducibility of the automated
phosphopeptide enrichment platform, combined with the
ability to process multiple technical and biological replicates,
rigorous statistical analysis of label-free phosphoproteomic data
can be performed (Supplementary Figure 9c, Supporting
Information). For example, signiﬁcantly regulated MAPK1/3
phosphorylation was observed across all biological conditions
(Figure 5c). In addition, multivariate analysis revealed
phosphosites that were consistently and signiﬁcantly regulated
across all three distinct cell isolations (Figure 5d). By
processing 54 samples across multiple cell lines and biological
replicates, the automated phosphopeptide enrichment platform
identiﬁed a core panel of signiﬁcantly KRAS-G12D regulated
phosphosites common to all PDA cells (Supplementary Table
4, Supporting Information).
Given its ability to process large numbers of distinct
biological samples in a uniform manner, we propose automated
phosphopeptide enrichment as a robust platform for statistical
investigation of multivariate phosphoproteomic experiments.
■ CONCLUSIONS
As all reagents and equipment are readily available, the reported
automated phosphopeptide enrichment platform can be easily
implemented across multiple laboratories interested in
phosphoproteomic analysis. Given the rapid (45 min),
reproducible (r2 = 0.80) and high-ﬁdelity (>90% phosphopep-
tide purity) properties of this approach, we propose automated
magnetic phosphopeptide enrichment as an easily accessible
method for uniform phosphopeptide enrichment.
Figure 4. Automated phosphopeptide enrichment interplate reprodu-
cibility. Daily automated phosphopeptide enrichments of a common
100 μg sample of tryptic digest were performed across 5 consecutive
days. Enrichments were conducted using (a) 1 mg of TiO2, (b) 1 mg
of Ti-IMAC, and (c) 1 mg of a mixture of TiO2 and Ti-IMAC (n = 3/
day). The respective precursor areas for each phosphopeptide were
calculated and Pearson correlated across all 5 days. Two-tailed test for
all correlations P < 0.0001. LC-MS/MS DDA runs n = 45.
Figure 5. Multivariate sample automated phosphopeptide enrichment. (a) Experimental workﬂow. (b) PCA of label-free phosphoproteomic
quantiﬁcation resolves WT and G12D KRAS genotypes. (c) Signiﬁcant phosphorylated MAPK1 (T183/Y185) and MAPK3 (T203/Y205) following
oncogenic KRAS (biological replicates; two-tailed t-test; *<0.05, **<0.01, ***<0.001). (d) Signiﬁcant diﬀerentially phosphorylated peptides across
all three cell lines (two-tailed t-test <0.05). (Annotated data in Supplementary Table 4, Supporting Information). LC-MS/MS DDA runs n = 54.
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